SCHEMBL2607452

SCHEMBL2607452

Cc1ccc(-n2c(-c3ccc(S(C)(=O)=O)cc3)nc3cncnc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.49
PTGS1 P23219 4/20 0.46
CYP3A4 P08684 4/20 0.46
CYP1A2 P05177 4/20 0.46
ALDH1A1 P00352 3/20 0.46
CYP2C9 P11712 3/20 0.46
HSD17B10 Q99714 3/20 0.46
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
USP2 O75604 3/20 0.43
MAPK1 P28482 2/20 0.43
CYP2C19 P33261 1/20 0.43
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2607449 0.91 CYP1A2 (0.53) PTGS2CYP3A4CYP1A2ALDH1A1CYP2C9
SCHEMBL2602427 0.89 CA1 (0.51) PTGS2PTGS1CYP3A4CYP1A2ALDH1A1
SCHEMBL2602374 0.88 CYP1A2 (0.52) CYP3A4CYP1A2ALDH1A1CYP2C9HSD17B10
SCHEMBL2607446 0.86 CYP1A2 (0.51) PTGS2CYP3A4CYP1A2ALDH1A1CYP2C9
SCHEMBL2607669 0.86 CYP1A2 (0.48) PTGS2CYP3A4CYP1A2ALDH1A1CYP2C9
SCHEMBL2607565 0.86 CYP1A2 (0.48) PTGS2CYP3A4CYP1A2ALDH1A1CYP2C9
SCHEMBL2607432 0.86 CYP3A4 (0.41) PTGS2CYP3A4CYP1A2ALDH1A1CYP2C9
SCHEMBL2607427 0.86 CYP1A2 (0.48) PTGS2CYP3A4CYP1A2ALDH1A1CYP2C9
SCHEMBL2607311 0.85 CYP1A2 (0.45) PTGS2PTGS1CYP3A4CYP1A2ALDH1A1
SCHEMBL2607566 0.81 CYP1A2 (0.49) CYP3A4CYP1A2ALDH1A1CYP2C9HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095027-A1 SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES SPELMAN COLLEGE (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095027-A1 SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES TYMP, MKI67, CCNI PTGS2 722/4885PTGS1 533/4885CYP3A4 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.